Skip to main content
Erschienen in: Supportive Care in Cancer 7/2015

01.07.2015 | Original Article

Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6

verfasst von: Luis García de Guadiana-Romualdo, Ignacio Español-Morales, Pablo Cerezuela-Fuentes, Luciano Consuegra-Sánchez, Ana Hernando-Holgado, Patricia Esteban-Torrella, Enrique Jiménez-Santos, Monserrat Viqueira-González, África de Béjar-Almira, María Dolores Albaladejo-Otón

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Early detection of infection is essential for initial management of cancer patients with chemotherapy-associated febrile neutropenia in the emergency department. In this study, we evaluated lipopolysaccharide binding protein (LBP) as predictor for infection in febrile neutropenia and compared with other biomarkers previously studied: C-reactive protein (CRP), procalcitonin (PCT), and interleukin (IL)-6.

Methods

A total of 61 episodes of chemotherapy-associated febrile neutropenia in 58 adult cancer patients were included. Serum samples were collected on admission at emergency department and CRP, LBP, PCT, and IL-6 were measured. Patients were classified into fever of unknown origin and infection, including microbiologically and clinically documented infection, groups. Receiver operating characteristic (ROC) curve analysis was performed for each biomarker for the diagnosis of infection.

Results

Thirty-two of the 61 episodes were classified as infection. On admission, CRP, PCT, IL-6, and LBP were significantly increased in patients with infection compared to fever of unknown origin group. Area under the ROC curve (AUC ROC) of CRP, PCT, IL-6, and LBP for discriminating both groups was 0.77, 0.88, 0.82, and 0.82, respectively, without significant difference between them. The combination of IL-6 and PCT or LBP did not lead to a significant improvement of the diagnostic accuracy of PCT or LBP alone.

Conclusions

On admission, LBP has a similar diagnostic accuracy than PCT or IL-6 for the diagnosis of infection and might be used as additional diagnostic tool in adult cancer patients with chemotherapy-associated febrile neutropenia.
Literatur
1.
Zurück zum Zitat Oude Nijhuis CS, Daenen SM, Vellenga E et al (2002) Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 44:163–174CrossRefPubMed Oude Nijhuis CS, Daenen SM, Vellenga E et al (2002) Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 44:163–174CrossRefPubMed
2.
Zurück zum Zitat Innes HE, Smith DB, O’Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89:43–49CrossRefPubMedCentralPubMed Innes HE, Smith DB, O’Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89:43–49CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Lingaratnam S, Worth LJ, Slavin MA et al (2011) A cost analysis of febrile neutropenia management in Australia: ambulatory v.s in-hospital treatment. Aust Health Rev 35:491–500PubMed Lingaratnam S, Worth LJ, Slavin MA et al (2011) A cost analysis of febrile neutropenia management in Australia: ambulatory v.s in-hospital treatment. Aust Health Rev 35:491–500PubMed
4.
Zurück zum Zitat Klastersky J, Awada A, Paesmans M et al (2011) Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 78:185–194CrossRefPubMed Klastersky J, Awada A, Paesmans M et al (2011) Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 78:185–194CrossRefPubMed
5.
Zurück zum Zitat de Bont ES, Vellenga E, Swaanenburg JC et al (1999) Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 107:375–380CrossRefPubMed de Bont ES, Vellenga E, Swaanenburg JC et al (1999) Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 107:375–380CrossRefPubMed
6.
Zurück zum Zitat von Lilienfeld-Toal M, Dietrich MP, Glasmacher A et al (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Dis 23:539–544 von Lilienfeld-Toal M, Dietrich MP, Glasmacher A et al (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Dis 23:539–544
7.
Zurück zum Zitat Kim Y, Lee Y, Ahn S et al (2011) The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat 43:176–180CrossRefPubMedCentralPubMed Kim Y, Lee Y, Ahn S et al (2011) The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat 43:176–180CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Jimeno A, García A, del Val O et al (2004) Assessment of procalcitonin as a diagnostic and prognostic Marker in Patients with Solid Tumors and Febrile Neutropenia. Cancer 100:2462–2469CrossRefPubMed Jimeno A, García A, del Val O et al (2004) Assessment of procalcitonin as a diagnostic and prognostic Marker in Patients with Solid Tumors and Febrile Neutropenia. Cancer 100:2462–2469CrossRefPubMed
9.
Zurück zum Zitat Urbonas V, Eidukaité A, Tamuliené I (2012) Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patients. Cytokine 57:313–315CrossRefPubMed Urbonas V, Eidukaité A, Tamuliené I (2012) Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patients. Cytokine 57:313–315CrossRefPubMed
10.
Zurück zum Zitat Reitman AJ, Pisk RM, Gates JV et al (2012) Serial procalcitonin levels to detect bacteremia in febrile neutropenia. Clin Pediatr (Phila) 51:1175–1183CrossRef Reitman AJ, Pisk RM, Gates JV et al (2012) Serial procalcitonin levels to detect bacteremia in febrile neutropenia. Clin Pediatr (Phila) 51:1175–1183CrossRef
11.
Zurück zum Zitat Mian A, Becton D, Saylors R et al (2012) Biomarkers for risk stratification of febrile neutropenia among children with malignancy: a pilot study. Pediatr Blood Cancer 59:238–245CrossRefPubMed Mian A, Becton D, Saylors R et al (2012) Biomarkers for risk stratification of febrile neutropenia among children with malignancy: a pilot study. Pediatr Blood Cancer 59:238–245CrossRefPubMed
12.
Zurück zum Zitat Miedema KG, de Bont ES, Elferink RF et al (2011) The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 19:1593–1600CrossRefPubMedCentralPubMed Miedema KG, de Bont ES, Elferink RF et al (2011) The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 19:1593–1600CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Hatzistilianou M, Rekliti A, Athanassiadou F et al (2010) Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res 59:339–347CrossRefPubMed Hatzistilianou M, Rekliti A, Athanassiadou F et al (2010) Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res 59:339–347CrossRefPubMed
14.
Zurück zum Zitat Diepold M, Noellke P, Duffner U et al (2008) Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis 8:28CrossRefPubMedCentralPubMed Diepold M, Noellke P, Duffner U et al (2008) Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis 8:28CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Prat C, Sánchez JM, Domínguez J et al (2008) Evaluation of procalcitonin, neopterin, C-protein reactive, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 49:1572–1581CrossRef Prat C, Sánchez JM, Domínguez J et al (2008) Evaluation of procalcitonin, neopterin, C-protein reactive, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 49:1572–1581CrossRef
16.
Zurück zum Zitat Ortega M, Rovira M, Filella X et al (2004) Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 126:372–376CrossRefPubMed Ortega M, Rovira M, Filella X et al (2004) Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 126:372–376CrossRefPubMed
17.
Zurück zum Zitat Robinson JO, Lamoth F, Bally F et al (2011) Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 6:e18886CrossRefPubMedCentralPubMed Robinson JO, Lamoth F, Bally F et al (2011) Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 6:e18886CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Oude Nijhuis CS, Vellenga E, Daenen SM et al (2003) Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients. Intensive Care Med 29:2157–2161CrossRefPubMed Oude Nijhuis CS, Vellenga E, Daenen SM et al (2003) Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients. Intensive Care Med 29:2157–2161CrossRefPubMed
19.
Zurück zum Zitat Kitanovski L, Jazbec J, Hojker S et al (2014) Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer 22:269–277CrossRefPubMed Kitanovski L, Jazbec J, Hojker S et al (2014) Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer 22:269–277CrossRefPubMed
20.
Zurück zum Zitat Schumann R, Zweigner J (1999) A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med 37:271–274CrossRefPubMed Schumann R, Zweigner J (1999) A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med 37:271–274CrossRefPubMed
21.
Zurück zum Zitat Zweigner J, Schumann RR, Wener JR (2006) The role of lipopoysaccharide binding protein in modulating the innate immune response. Microbes Infect 8:946–952CrossRefPubMed Zweigner J, Schumann RR, Wener JR (2006) The role of lipopoysaccharide binding protein in modulating the innate immune response. Microbes Infect 8:946–952CrossRefPubMed
22.
Zurück zum Zitat Faure E, Equils O, Sieling PA (2000) Bacterial lypopolysaccharide activates NF-KappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 275:11058–11063CrossRefPubMed Faure E, Equils O, Sieling PA (2000) Bacterial lypopolysaccharide activates NF-KappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 275:11058–11063CrossRefPubMed
23.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenia cancer patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenia cancer patients. J Clin Oncol 18:3038–3051PubMed
24.
Zurück zum Zitat Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMed Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMed
25.
Zurück zum Zitat Levy MM, Fink MP, Marshall JC et al (2003) International Sepsis Definitions Conference: SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference Levy MM, Fink MP, Marshall JC et al (2003) International Sepsis Definitions Conference: SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference
27.
Zurück zum Zitat Cisneros JM, Cobo J, Pujol M et al (2007) Guía para el diagnóstico y tratamiento del paciente con bacteriemia. Guías de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Enferm Infecc Microbiol Clin 25:111–130CrossRef Cisneros JM, Cobo J, Pujol M et al (2007) Guía para el diagnóstico y tratamiento del paciente con bacteriemia. Guías de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Enferm Infecc Microbiol Clin 25:111–130CrossRef
28.
Zurück zum Zitat Talcott JA, Finberg R, Mayer RJ et al (1988) Risk assessment in cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561–2568CrossRefPubMed Talcott JA, Finberg R, Mayer RJ et al (1988) Risk assessment in cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561–2568CrossRefPubMed
29.
Zurück zum Zitat Sakr Y, Sponholz C, Tuche F et al (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407CrossRefPubMed Sakr Y, Sponholz C, Tuche F et al (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407CrossRefPubMed
30.
Zurück zum Zitat Julián-Jiménez A, Candel-González FJ, González del Castillo J (2014) Utilidad de los biomarcadores de inflamación e infección en los servicios de urgencias. Enferm Infecc Microbiol Clin 32:177–190CrossRefPubMed Julián-Jiménez A, Candel-González FJ, González del Castillo J (2014) Utilidad de los biomarcadores de inflamación e infección en los servicios de urgencias. Enferm Infecc Microbiol Clin 32:177–190CrossRefPubMed
31.
Zurück zum Zitat Riedel S (2012) Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 73:221–227CrossRefPubMed Riedel S (2012) Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 73:221–227CrossRefPubMed
32.
Zurück zum Zitat Gómez-Gerique JA, Ortiz-Espejo M, Torrealba-Rodríguez M et al (2010) Evaluación de la capacidad diagnóstica y pronóstica de procalcitonina, proteína C reactiva, interleucina-6 y proteína fijadora del lipopolisacárido en pacientes con sospecha de sepsis. Rev Lab Clin 3:12–19 Gómez-Gerique JA, Ortiz-Espejo M, Torrealba-Rodríguez M et al (2010) Evaluación de la capacidad diagnóstica y pronóstica de procalcitonina, proteína C reactiva, interleucina-6 y proteína fijadora del lipopolisacárido en pacientes con sospecha de sepsis. Rev Lab Clin 3:12–19
33.
Zurück zum Zitat Ratzinger F, Schuardt M, Eichbichler K et al (2013) Utility of sepsis biomarkers and the infection probability score to discriminate sepsis and systemic inflammatory response syndrome in standard care patients. PLoS One 8:e82946CrossRefPubMedCentralPubMed Ratzinger F, Schuardt M, Eichbichler K et al (2013) Utility of sepsis biomarkers and the infection probability score to discriminate sepsis and systemic inflammatory response syndrome in standard care patients. PLoS One 8:e82946CrossRefPubMedCentralPubMed
34.
Zurück zum Zitat Engel A, Steinbach G, Kern P et al (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31:185–189CrossRefPubMed Engel A, Steinbach G, Kern P et al (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31:185–189CrossRefPubMed
35.
Zurück zum Zitat Schuetz P, Amin DN, Greenwald JL (2012) Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 141:1063–1073CrossRefPubMed Schuetz P, Amin DN, Greenwald JL (2012) Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 141:1063–1073CrossRefPubMed
36.
Zurück zum Zitat Kaya S, Köksal I, Mentese A et al (2013) The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. Int J Infect Dis 17:e1056–e1059CrossRefPubMed Kaya S, Köksal I, Mentese A et al (2013) The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. Int J Infect Dis 17:e1056–e1059CrossRefPubMed
37.
Zurück zum Zitat Gac AC, Parienti JJ, Chantepie S et al (2011) Dynamics of procalcitonin and bacteremia in neutropenic patients with acute myeloid leukaemia. Leuk Res 35:1294–1296CrossRefPubMed Gac AC, Parienti JJ, Chantepie S et al (2011) Dynamics of procalcitonin and bacteremia in neutropenic patients with acute myeloid leukaemia. Leuk Res 35:1294–1296CrossRefPubMed
38.
Zurück zum Zitat Kwofie L, Rapoport BL, Fickl H et al (2012) Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients eith chemotherapy-associated febrile neutropenia: a pilot study. Ann Hematol 91:605–611CrossRefPubMed Kwofie L, Rapoport BL, Fickl H et al (2012) Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients eith chemotherapy-associated febrile neutropenia: a pilot study. Ann Hematol 91:605–611CrossRefPubMed
39.
Zurück zum Zitat Tan BH, Png ME, Yeo CP, Wong GC (2014) Procalcitonin in febrile neutropenia-timing is important. Support Care Cancer 22:583–584CrossRefPubMed Tan BH, Png ME, Yeo CP, Wong GC (2014) Procalcitonin in febrile neutropenia-timing is important. Support Care Cancer 22:583–584CrossRefPubMed
Metadaten
Titel
Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6
verfasst von
Luis García de Guadiana-Romualdo
Ignacio Español-Morales
Pablo Cerezuela-Fuentes
Luciano Consuegra-Sánchez
Ana Hernando-Holgado
Patricia Esteban-Torrella
Enrique Jiménez-Santos
Monserrat Viqueira-González
África de Béjar-Almira
María Dolores Albaladejo-Otón
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2589-1

Weitere Artikel der Ausgabe 7/2015

Supportive Care in Cancer 7/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.